Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Monday, October 31, 2016

Novel Alzheimer's treatment uses microscopic droplets of fat to carry drugs into the brain

If we ever get a drug developed that would help stroke recovery this could be used to deliver it to the brain. As long as we have someone keeping track of a stroke strategy and all the moving parts that need to be remembered.  Or maybe these 13 nasal delevery options? I bet no one in stroke is keeping track of this.
http://www.news-medical.net/news/20161020/Novel-Alzheimers-treatment-uses-microscopic-droplets-of-fat-to-carry-drugs-into-the-brain.aspx
New Alzheimer's treatment could be delivered as nasal spray
Researchers have developed a novel treatment that could block the development of Alzheimer's disease using microscopic droplets of fat to carry drugs into the brain. This treatment approach, which is used to target drugs to cancer cells, has been successfully applied to Alzheimer's disease for the first time, restoring memory loss in mice.
The study, which was led by researchers at Lancaster University and funded by Alzheimer's Society, is published  in the journal Nanomedicine: Nanotechnology, Biology and Medicine.
The treatment uses tiny droplets of fat, called nanoliposomes, which are coated in protein fragments that are able to stop amyloid protein accumulating into plaques, even at low concentrations. Amyloid plaques are the toxic clumps of protein that cause damage to cells in the brains of people with Alzheimer's disease.
Mice that were genetically altered to develop Alzheimer's disease were injected with the nanoliposomes for three weeks. Those which received the drug recovered their long-term memory and could recognise familiar objects after a 24-hour period. In comparison, mice which received a placebo injection had no memory of objects seen the day before.
Lead researcher, Professor David Allsop, commented: "Following results this summer, there is renewed optimism for antibody drugs - treatments that harness the body's immune system to target amyloid plaques. However if these prove successful, treatments will have to be administered in a clinic by an IV drip and could have some potentially harmful side effects.
"Using nanoliposomes offers an alternative way to inhibit the toxic build-up of amyloid plaques without activating an immune response in the brain. Our hope is that this could one day be administered by something as simple and non-invasive as a nasal spray, which patients could use in the comfort of their own home."
Nanoliposomes are already used to better target toxic chemotherapy drugs to cancer cells. Recent studies have also shown that the fat droplets can pass directly into the brain through the nose, opening up the possibility of using a nasal spray to administer treatments for brain diseases, such as Alzheimer's.
Commenting on the need for innovative approaches to dementia treatments, Dr Doug Brown, Director of Research and Development at Alzheimer's Society, said: "With no new dementia drugs in nearly 15 years, we're at a critical time for dementia research. It's absolutely vital we continue to sniff-out new approaches to getting drugs into the brain. While we wait in anticipation for the results of ongoing clinical trials, Alzheimer's Society will continue to fund innovative research to tackle dementia head-on."
"Nanotechnology is promising great benefits to people with many different types of cancer, and it's exciting that it could one day offer the same hope to people with the most common form of dementia." 
There are 850,000 people in the UK living with dementia, and currently available drugs are only able to treat the symptoms of dementia, rather than slowing its progression. The research team at Lancaster University are now seeking investment from industry to take their novel treatment forward to be tested in people.
Source:
Lancaster University

No comments:

Post a Comment